Congenital Disorders of Glycosylation (CDG): A Rapidly Expanding Group of Neurometabolic Disorders

作者
Stephanie Grünewald,Gert Matthijs
出处
期刊:Neuropediatrics [Thieme Medical Publishers (Germany)]
卷期号:31 (2): 57-59 被引量:17
标识
DOI:10.1055/s-2000-7487
摘要

The recently delineated Congenital Disorders of Glycosylation (CDG), formerly known as Carbohydrate-Deficient Glycoprotein syndromes, are a group of inherited multisystem diseases due to defective N-glycosylation of proteins. Protein glycosylation is a frequent posttranslational modification and many secreted and membranous proteins have covalently bound carbohydrate units. These serve a variety of functions, allowing correct folding of the proteins, their protection against proteases and modulation of their biological activities [[ 17 ]]. The biosynthesis of N-linked oligosaccharides is elaborate and numerous glycosyltransferases are involved, attaching sugars to a growing lipid-linked oligosaccharide chain, stepwise. The donors are either nucleotide-activated or dolichol phosphate-linked sugars for these transfer reactions. Finally, the completed structure (Gluc 3 Man 9 GlcNAc 2 ) is transposed en bloc within the endoplasmatic reticulum (ER). It is then attached to an asparagine residue of a nascent protein via the oligosaccharyltransferase complex. In the Golgi compartment, several glycosidases can remodel the oligosaccharide chain into a more complex structure by removal of mannose residues and the addition of N-acetylglucosamine, galactose, fucose and sialic acid residues [[ 13 ]]. Considering the ubiquitous presence of glycosylation and the multiple functions of the glycans, it is obvious that defects in the biosynthesis of N-glycoproteins will be detrimental and result in a broad spectrum of clinical signs and symptoms. In 1980, Jaeken and colleagues described the first patients retrospectively diagnosed as CDG-Ia, with multisystem involvement including developmental delay, dysmorphic features and endocrine and biochemical abnormalities [[ 7 ]]. From the early 80s, isoelectric focussing (IEF) of serum transferrin has been a powerful tool to search for defects of N-glycosylation. When a protein is hypoglycosylated, the number of negatively charged sialic acids of serum transferrin is diminished, which results in a cathodal shift in IEF. This test, however, cannot distinguish between different types of CDG and additional studies must be performed to reach a definitive diagnosis. In the last few years, many new patients were identified with an abnormal transferrin pattern. Up to now six different defects were delineated. Much of the recent progress was achieved by taking advantage of what is known in yeast: the early steps in N-glycosylation are highly conserved between eukaryotes, and yeast mutants have proven to be a powerful tool in the characterisation of novel types of CDG-I. In contrast to other metabolic disorders, in which defects are restricted to one organelle, the enzyme defects in CDG are found in the cytosol, the ER and the Golgi compartment. The decreased activity of two cytosolic enzymes, phosphomannomutase 2 (in CDG-Ia) [[ 14 ], [ 16 ]] and phosphomannose isomerase (in CDG-Ib) [[ 9 ]] result in a depletion of the GDP-mannose pool, required for the biosynthesis of the lipid-linked oligosaccharide chain (LLO). Deficiencies of the ER located α-1,3 glycosyltransferase (in CDG-Ic) [[ 1 ], [ 5 ], [ 11 ]] and the α-1,3 mannosyltransferase (in CDG-Id) [[ 12 ]] impair the assembly of the LLO. Mutations in a gene coding for a subunit of the dolichol-phosphate mannose synthase (in CDG-Ie) [[ 6 ], [ 10 ]] result in a shortage of the donor molecule phosphate mannose. The new classification (Table 1 ) follows the recommendations of a group of experts in the field at the “First International Workshop on CDGS” (November 1999 in Leuven, Belgium). This nomenclature no longer primarily refers to the transferrin pattern in IEF, but rather divides CDG in two groups, on the basis of the localisation of the enzymatic defect in the biosynthetic pathway of N-glycans. Disorders which affect the assembly of the dolichylpyrophosphate-linked oligosaccharide and/or its transfer to the asparagine residues on the nascent polypeptide are classified as CDG-I. CDG-II comprises the defects in the subsequent processing of the protein-bound glycans. The latter group includes CDG-IIa which results from a reduced N-acetylglucosaminyltransferase II activity [[ 15 ]]. Although all disorders grouped as CDG-I result from a defective assembly or transport of the LLO, the corresponding patients display distinctive symptoms. Most patients with CDG-I present with mild to severe neurologic dysfunction and developmental delay. CDG-Ia represent the majority of cases, and patients classically show dysmorphic features, moderate to severe psychomotor retardation and a variable non-neurological involvement with inverted nipples, abnormal fat distribution and cerebellar hypoplasia [[ 8 ]]. The latter triad has been the hallmark of CDG. However, a few patients known to have CDG-Id and CDGT-Ie lack this triad and still have a severe form of the disease. In contrast, CDG-Ib patients present with almost exclusively hepato-intestinal symptoms. CDG-Ic is different again. In this issue of Neuropediatrics, Hanefeld and colleagues point out that the clinical presentation in a young girl closely resembles a mild form of CDG-Ia. Abnormal results for clotting factors, low values for thyroxin in addition to unusual clinical features, prompted the authors to perform the IEF of serum transferrin. LLO-analyses of patient's fibroblasts revealed an accumulation of Man 9 GlcNAc 2 structures and metabolic studies documented an α-1, 3 glucosyltransferase deficiency [[ 11 ]]. The molecular studies now show that the patient is homozygous for an in-frame deletion at position 299, confirming the diagnosis of CDG-Ic. There is a striking similarity of the clinical picture of the present case with that of 8 other CDG-Ic patients, who were all homozygous for an A333 V mutation [[ 4 ]]. However, a slow progressive cerebellar atrophy of postnatal onset has not been observed before in CDG-Ic. It demonstrates the variable clinical course in CDG-Ic, probably due to different mutations in the disease gene. This report illustrates again the broad clinical spectrum of CDG and it is unlikely that the full clinical spectrum of these disorders has been delineated yet. CDG should be suspected: 1. in patients presenting with the cardinal symptoms of CDG-Ia and CDG-Ib (inverted nipples, abnormal fat distribution, cerebellar hypoplasia or protein-loosing enteropathy) and 2. in children with a combination of symptoms frequently associated with CDG (failure to thrive, muscular hypotonia, mental retardation, epilepsy, retinitis pigmentosa and/or abnormalities in laboratory results of glycoproteins). So far the IEF of serum transferrin has been used to identify N-glycosylation defects with glycoprotein abnormalities of serum proteins. Recently, the first indication that defects in the biosynthesis of N-glycoproteins may be limited to the central nervous system was found in the study on β-trace protein, a N-glycoprotein synthesised in brain [[ 3 ]]. Not only will these and further investigations give us some insights into the pathogenic role of hypoglycosylation in brain, they also indicate that other diagnostic tools will be necessary. These are exciting times for people involved in CDG. Within months, CDG-Ic, CDG-Id and CDG-Ie were added to the list of known disorders. In the near future, it seems certain that more disorders will emerge, in particular in CDG-II. The complexity of CDG-II will exceed that of CDG-I because of the complexity of the processing of the N- and O-glycan in the Golgi. Camillo Golgi (1843 - 1926) initiated basic research work on this tangled compartment. He was awarded the Nobel Prize in 1906 for his silver osmium staining technique (the “reazione nera”) [[ 2 ]]. 25 years had been necessary to discover the “apparato reticolare interno”. Now, a hundred years later, we are still far away from fully understanding this complex compartment, but progress in CDG research might give some more light and insight to these most interesting structures.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pyb发布了新的文献求助20
刚刚
刚刚
刚刚
搜集达人的应助被yuan采纳,获得10
刚刚
刚刚
2秒前
Wdd完成签到,获得积分10
2秒前
2秒前
王铂然发布了新的文献求助10
2秒前
TT发布了新的文献求助10
3秒前
猫咪ag完成签到,获得积分10
4秒前
4秒前
Xiiiii9完成签到,获得积分10
4秒前
没得发布了新的文献求助10
5秒前
6秒前
hxy90发布了新的文献求助10
7秒前
8秒前
丘比特的应助被匆匆采纳,获得10
8秒前
8秒前
桐桐的应助被ayeben采纳,获得10
8秒前
秋风的应助被糯米饭采纳,获得30
9秒前
Wen完成签到 ,获得积分10
9秒前
9秒前
Huaaaaay完成签到 ,获得积分10
10秒前
wanci的应助被yb采纳,获得10
10秒前
10秒前
香蕉觅云的应助被yu采纳,获得10
10秒前
昭仪完成签到 ,获得积分10
10秒前
烟花的应助被燕然都护采纳,获得10
11秒前
万能图书馆的应助被王长长采纳,获得10
11秒前
cfplhys完成签到,获得积分10
11秒前
11秒前
汤雪婷完成签到,获得积分10
11秒前
打打的应助被瓦洛佳小神采纳,获得10
11秒前
Atom发布了新的文献求助10
12秒前
领导范儿的应助被dawei采纳,获得10
13秒前
13秒前
mmddlj完成签到 ,获得积分10
13秒前
梨涡完成签到 ,获得积分10
13秒前
陈雯完成签到 ,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192477
求助须知:如何正确求助?哪些是违规求助? 9578972
关于积分的说明 21863066
捐赠科研通 7791984
什么是DOI,文献DOI怎么找? 3436955
关于科研通互助平台的介绍 2560616
邀请新用户注册赠送积分活动 2483791